Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE.

J Thorac Oncol. 2016 Apr;11(4):556-65. doi: 10.1016/j.jtho.2015.12.103. Epub 2015 Dec 25.

2.

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE.

Eur J Radiol. 2015 May;84(5):998-1004. doi: 10.1016/j.ejrad.2015.01.021. Epub 2015 Feb 7.

3.

Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.

Romanus D, Cardarella S, Cutler D, Landrum MB, Lindeman NI, Gazelle GS.

J Thorac Oncol. 2015 Apr;10(4):586-94. doi: 10.1097/JTO.0000000000000474.

4.

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE.

Cancer. 2013 Nov 1;119(21):3761-8. doi: 10.1002/cncr.28290. Epub 2013 Aug 6.

5.

The impact of genomic changes on treatment of lung cancer.

Cardarella S, Johnson BE.

Am J Respir Crit Care Med. 2013 Oct 1;188(7):770-5. doi: 10.1164/rccm.201305-0843PP. Review.

6.

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C, Yeap BY, Sholl LM, Johnson BE, Jänne PA.

Clin Cancer Res. 2013 Aug 15;19(16):4532-40. doi: 10.1158/1078-0432.CCR-13-0657. Epub 2013 Jul 5.

7.

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

Nishino M, Cardarella S, Jackman DM, Ramaiya NH, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

AJR Am J Roentgenol. 2013 Jul;201(1):W64-71. doi: 10.2214/AJR.12.9668.

8.

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE.

J Thorac Oncol. 2013 Aug;8(8):1059-68. doi: 10.1097/JTO.0b013e318294c909.

9.

Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts.

Cardarella S, Johnson BE.

J Natl Cancer Inst. 2013 May 1;105(9):589-90. doi: 10.1093/jnci/djt085. Epub 2013 Apr 17. No abstract available.

PMID:
23594425
10.

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE.

Lung Cancer. 2013 Mar;79(3):283-8. doi: 10.1016/j.lungcan.2012.11.007. Epub 2012 Dec 14.

11.

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Jänne PA, Lindeman NI, Johnson BE.

J Thorac Oncol. 2012 Dec;7(12):1767-1774. doi: 10.1097/JTO.0b013e3182745bcb.

Supplemental Content

Loading ...
Support Center